AbCellera Biologics Inc.

NASDAQ: ABCL · Real-Time Price · USD
4.58
0.08 (1.78%)
At close: Aug 15, 2025, 3:59 PM
4.61
0.66%
After-hours: Aug 15, 2025, 07:54 PM EDT

AbCellera Biologics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
28.83M 38.02M 485.42M 375.2M
Cost of Revenue
97M 30.89M 66.44M 45.52M
Gross Profit
-68.17M 7.13M 418.99M 329.69M
Operating Income
-314.77M -237.21M 216.51M 204.41M
Interest Income
38.47M 42.25M 16.08M 3.33M
Pretax Income
-200.4M -174.03M 239.1M 219.15M
Net Income
-162.86M -146.4M 158.52M 153.46M
Selling & General & Admin
85.49M 75.18M 66.75M 48.76M
Research & Development
167.26M 175.66M 107.88M 62.06M
Other Expenses
90.85M 24.39M 17.29M -3.04M
Operating Expenses
343.6M 275.23M 191.92M 107.79M
Interest Expense
n/a n/a 4.04M 5.22M
Selling & Marketing Expenses
12.78M 14.18M 11.27M 6.91M
Cost & Expenses
343.6M 275.23M 258.36M 153.3M
Income Tax Expense
-37.54M -27.63M 80.58M 65.69M
Shares Outstanding (Basic)
294.33M 289.17M 285.06M 275.76M
Shares Outstanding (Diluted)
294.33M 289.17M 314.83M 318.29M
EPS (Basic)
-0.55 -0.51 0.56 0.56
EPS (Diluted)
-0.55 -0.51 0.50 0.48
EBITDA
-204.15M -192.16M 272.2M 241.62M
EBIT
-301.15M -223.05M 227.06M 204.41M
Depreciation & Amortization
97M 30.89M 33.1M 17.25M